Expanded Telehealth Access Act
Summary
The Expanded Telehealth Access Act (S.3834) is an early-stage Senate bill that permanently adds audiologists, physical therapists, occupational therapists, speech-language pathologists, and assistants to Medicare telehealth eligibility. No funding is authorized. Market data shows mixed conviction: TDOC down 4.87% in the last 7 days to $5.47, while AMWL gained 3.06% to $6.06, indicating no material premium is priced in for this low-probability legislative event.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S.3834 is an early-stage bill with zero funding and minimal sponsorship — low probability of passage in the 119th Congress.
- 2.If enacted, it would create a structural tailwind for telehealth platforms by expanding the eligible Medicare provider pool, but no near-term revenue impact.
- 3.Current market pricing reflects no premium for this legislation: TDOC is down 4.87% and AMWL up 3.06% in the last 7 days, consistent with normal volatility, not legislative anticipation.
Market Implications
The market is correctly pricing this bill as immaterial. TDOC at $5.47 trades at a 44% discount to its 52-week high of $9.77, reflecting company-specific challenges (declining visit volumes, competitive pressure). AMWL at $6.06 sits 34% below its 52-week high of $9.15, with a 15% 30-day gain that likely reflects general sector rotation into small-cap healthcare IT. Neither stock's price action correlates with the February 11 bill introduction — both traded sideways through February and March. Investors should not allocate capital based on S.3834 until it advances out of committee, which requires a Finance Committee markup — none is scheduled.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Regulatory expansion: permanently adds audiologists, physical therapists, occupational therapists, speech-language pathologists, and assistants to the list of Medicare-eligible telehealth providers under 42 U.S.C. 1395m(m). No new funding authorized.
Who must act
Centers for Medicare & Medicaid Services (CMS) — must update Medicare payment rules to include these new practitioner types at distant sites.
What happens
Expands the addressable patient pool for telehealth services by enabling these therapy and audiology professionals to bill Medicare for remote consultations, increasing total potential telehealth visit volume in Medicare fee-for-service.
Stock impact
TDOC's primary revenue is from virtual care visits. Adding ~150,000+ physical therapists, occupational therapists, speech-language pathologists, and audiologists as potential platform users expands TDOC's addressable clinician base, but TDOC is not the exclusive platform — any telehealth platform can onboard these providers. Bill is early-stage, so no immediate revenue impact.
What the bill does
Same regulatory expansion: permanent addition of therapy and audiology practitioners to Medicare telehealth eligibility under Section 1834(m) of the Social Security Act.
Who must act
CMS — must update Medicare telehealth practitioner definitions and payment rules.
What happens
Expands the pool of clinicians who can independently use telehealth platforms for Medicare patients, increasing potential platform utilization and subscription revenue for vendors serving these disciplines.
Stock impact
AMWL's platform serves health systems and enterprise clients. Physical therapy, occupational therapy, and speech therapy are standard service lines in health systems — expanding their Medicare telehealth eligibility creates a tailwind for AMWL's enterprise contracts, but the bill is pre-committee with no near-term revenue trigger.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Second Chance Mental Health Access Act of 2026
To amend the Public Health Service Act to reauthorize the telehealth network and telehealth resource centers grant programs.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Integrating Financial Technology Innovation into Regulatory Frameworks
This executive order directs federal financial regulators to review and streamline regulations that hinder fintech innovation, particularly for small and emerging firms, and requests the Federal Reserve to evaluate expanding access to its payment accounts and services for non-bank and digital asset firms. It aims to reduce barriers to entry and encourage partnerships between fintech firms and traditional financial institutions, with specific deadlines for reviews and reports.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.